Events

Join EntityRisk and industry leaders for a discussion on how HEOR and Market Access professionals are navigating the evolving policy, access, and value landscapes.

Come visit us at Booth #805.

Darius Lakdawalla, PhD, Co-Founder and Chief Scientific Officer of EntityRisk and Chief Scientific Officer of the USC Schaeffer Center, will participate as a speaker to discuss how U.S. drug policies are reshaping innovation, evidence, and access globally.

Neal Masia, PhD, Co-Founder and CEO of EntityRisk, will speak at this ISPOR Workshop. He will discuss when development-stage biotechs should implement HEOR capabilities and how these teams can maximize an organization's clinical and commercial impact.

Neal Masia, PhD, Co-Founder and CEO of EntityRisk, will speak at this ISPOR Fast Facts Session. This session will examine how shifting global health policies and fragmented regulatory environments are reshaping pharmaceutical R&D, market prioritization, and the consequential effects.

This Issue Panel will examine the opportunities and limitations of the Health Economics Methods Advisory (HEMA) recommendations through a structured, multi-perspective debate. Darius Lakdawalla, PhD, Co-Founder and Chief Scientific Officer of EntityRisk and Chief Scientific Officer of the USC Schaeffer Center, will assess the conceptual foundations of the proposals and their relationship to emerging economic methods.

This issue panel will debate whose preferences should govern health technology adoption. Darius Lakdawalla, PhD, Co-Founder and Chief Scientific Officer of EntityRisk and Chief Scientific Officer of the USC Schaeffer Center, will present the case for incorporating individual-level risk preferences into value assessment and argue why such approaches may better align with welfare economics and decision-making.

Dana Goldman, PhD, Co-Founder and Scientific Advisor of EntityRisk and Director of the USC Schaeffer Center, will moderate the plenary to discuss the economic, regulatory, and long-term consequences of U.S. pharmaceutical policies in both the US and abroad.

Join EntityRisk and industry leaders for an exclusive forum on value-based pricing, evidence generation, and navigating evolving healthcare landscape

EntityRisk's Devin Incerti, PhD, will speak in this short course where participants will learn how to use R to develop a number of different types of economic models to perform cost-effectiveness analysis.